News

Trial Aim

The BM12 CAST trial focused on patients with acute myeloid leukaemia (AML) or acute lymphoblastic leukaemia (ALL) who received stem cell transplants from matched sibling donors. In this trial, patients were treated with a modified, less toxic two-drug treatment regimen. BM12 aimed to significantly lower rates of infection, rejection, and the debilitating complication Graft Versus Host Disease (GVHD).

Trial Impact

• The new treatment triples the chance for patients being alive, healthy and free of life-threatening complications such as Graft Versus Host Disease (GVHD) three years after transplant
• Less toxic treatment regimen with better outcomes for patients

Trial Aim

The ALL09 clinical trial investigated if incorporating a new immunotherapy blinatumomab into the standard chemotherapy regimen would result in better outcomes for adolescent and young adult patients with Acute Lymphoblastic Leukaemia (AYA). AYA patients experience a uniquely different cancer biology in their leukaemia when compared to adult and paediatric patients. Unfortunately, these patients also have markedly worse survival and relapse outcomes than both other patient groups.

ALL09 follows on from the ALLG ALL06 trial, which found that using the paediatric treatment protocol was effective in AYA patients, becoming
standard of care.

Trial Aim

AMLM26 INTERCEPT is a platform trial that aims to facilitate proof-of-concept development of new therapies/combinations by demonstrating effectiveness in
patients with rising MRD or early morphologic relapse. It enables new
therapies to be tested in healthier patients with better preserved bone
marrow function, for better outcomes.

AMLM26 INTERCEPT will enable patients to rotate to new treatment arms when there is evidence of MRD failure, guided by the best available evidence at the time. As a platform trial, the protocol will allow the addition of new treatment arms as new treatments are discovered.

Trial Impact

• This study represents how AML is likely to be managed in the future – with a focus on earlier, personalised and adaptive therapy
  A major advantage of this approach is the reduced treatment toxicity associated with earlier intervention, prior to the patient deteriorating clinically

Trial Aim

CML14 ASCENDANCE is investigating a new drug combination of asciminib
and dasatnib. It aims to minimise treatment failure for patients with
Chronic Myeloid Leukaemia (CML) who have additional genomic abnormalities in genes commonly associated with other myeloid
malignancies.

Trial Impact

• CML14 will assess the effectiveness of an induction phase of combination therapy with asciminib plus low dose dasatinib in newly diagnosed chronic phase CML with high risk genetics
• This treatment combination may support patients to achieve a major and deep molecular response in CML

Trial Aim

Although the majority of patients with Hodgkin lymphoma are cured with primary chemotherapy, up to 30% of patients will ultimately develop relapsed or refractory disease, despite the possibility of cure with autologous stem cell
transplantation. The HD11 trial aims to  prevent relapse and refractory
disease in patients with Hodgkin lymphoma who are eligible for high
dose chemotherapy and autologous stem cell transplant.

Trial Aim

Although the majority of patients with Hodgkin lymphoma are cured with primary chemotherapy, up to 30% of patients will ultimately develop relapsed or refractory disease, despite the possibility of cure with autologous stem cell transplantation. The HD11 trial aims to prevent relapse and refractory disease in patients with Hodgkin lymphoma who are eligible for high dose chemotherapy and autologous stem cell transplant.

Trial Impact

• Offers a chance of better survival outcomes for patients with few treatment options
• Using specialised anti-cancer drugs to target Hodgkin lymphoma cells

Trial Aim

Primary mediastinal B-cell lymphoma (PMBL) is an uncommon subtype of diffuse large B-cell lymphoma (DLBCL) that primarily affects young adults and comprises of 10% of DLBCL diagnoses. Outcomes for patients with relapsed/refractory  PMBL remain poor. Although the current treatment is effective, it doesn’t work for 10-20% of patients. There is a substantial need to design improvements in the initial therapy of patients with PMBL. The NHL35 trial is assessing the effectiveness and improval in event-free survival (18
months) of R-CHOP in combination with pembrolizumab in patients with
newly diagnosed PMBL.

Trial Impact

• Targets a high unmet need in the patient population of young adults with DLBCL
• Aims to reduce toxicity and has potential to increase remission rates and reduce relapse
• Positive results could change current standard of care

Trial Aim

MM24 IsAMP is an international phase 2, open label, multicentre, single-stage study that is assessing the effectiveness of a new treatment combination of Isatuximab plus Pomalidomide and Dexamethasone (IPd), in Amyloidosis patients who have not achieved Very Good Partial Response (VGPR) or better after any previous line of therapy. Amyloidosis is a rare disease that is caused by a build up of amyloid proteins in body tissues and organs, causing damage and impaired function.